# Wide excision and latissimus dorsi flap reconstruction for advanced axillary hidradenitis suppurativa: a case series

**Authors:** Frank Andrés Álvarez Vásquez, Iván Enrique Rodríguez Mantilla, Liceth Lorena Patarroyo Villalobos, Nicol Daniella Cala Gómez, Jorge Luis Corcho Acosta, Juan Pablo Zaraza Duarte

PMC · DOI: 10.1080/23320885.2026.2639268 · Case Reports in Plastic Surgery & Hand Surgery · 2026-02-28

## TL;DR

This paper presents three cases where advanced axillary hidradenitis suppurativa was treated with wide excision and latissimus dorsi flap reconstruction, resulting in good outcomes.

## Contribution

The study demonstrates the effectiveness of latissimus dorsi flap reconstruction for advanced axillary HS.

## Key findings

- All patients achieved durable coverage after surgery.
- Shoulder range of motion was preserved in all cases.
- No clinical recurrences were observed during follow-up.

## Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory disorder of the pilosebaceous unit characterized by recurrent nodules, tunnels, scarring, and functional impairment, most commonly affecting intertriginous regions. Surgical excision addresses irreversible tissue damage, while medical therapy controls the underlying inflammatory process; both strategies should be considered complementary. Following wide excision, secondary intention healing remains a valid option for axillary defects; however, flap reconstruction may be electively chosen in selected patients to shorten healing time and reduce wound care burden based on patient preference and surgeon experience. This article presents a case series of three patients with Hurley stage III axillary HS who underwent wide excision followed by reconstruction with latissimus dorsi musculocutaneous flaps. Operative details, perioperative management, postoperative outcomes, and follow-up are reported. All patients achieved durable coverage, preserved shoulder range of motion, high aesthetic satisfaction, and no clinical recurrences during follow-up.

## Linked entities

- **Diseases:** hidradenitis suppurativa (MONDO:0006559)

## Full-text entities

- **Genes:** IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}
- **Diseases:** postoperative (MESH:D019106), acne (MESH:D000152), stage III (MESH:D062706), Hurley stage III disease (MESH:D007676), infection (MESH:D007239), obesity (MESH:D009765), contracture (MESH:D003286), autoinflammatory disorder (MESH:D056660), ischemia (MESH:D007511), pain (MESH:D010146), HS (MESH:D017497), axillary defects (MESH:D000013), seroma (MESH:D049291), hematoma (MESH:D006406), metabolic syndrome (MESH:D024821), abscesses (MESH:D000038), inflammatory (MESH:D007249), Postoperative pain (MESH:D010149), malignancies (MESH:D009369)
- **Chemicals:** bimekizumab (MESH:C000625981), Monocryl (MESH:C095495), latissimus (-), methylene blue (MESH:D008751), clindamycin (MESH:D002981), adalimumab (MESH:D000068879), infliximab (MESH:D000069285), secukinumab (MESH:C555450), acetaminophen (MESH:D000082)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12951671/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12951671/full.md

## References

17 references — full list in the complete paper: https://tomesphere.com/paper/PMC12951671/full.md

---
Source: https://tomesphere.com/paper/PMC12951671